2016
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy
Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA, Collaboration A. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLOS ONE 2016, 11: e0160460. PMID: 27525413, PMCID: PMC4985160, DOI: 10.1371/journal.pone.0160460.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyLow CD4 countHIV-positive patientsAntiretroviral therapyCD4 countDrug useAntiretroviral Therapy Cohort CollaborationFive-year mortality riskAIDS infectionOlder ageCause-specific mortality rate ratiosNon-AIDS cancerLiver-related mortalityHIV Cohort StudyInjection drug useHIV-1 RNAMortality rate ratiosLiver-related diseasesHigh subsequent mortalityCohort CollaborationLow CD4Prior AIDSCardiovascular mortalityCohort studyPrognostic factors
2013
Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne J, Collaboration T. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal Of Epidemiology 2013, 43: 691-702. PMID: 23599235, PMCID: PMC4052127, DOI: 10.1093/ije/dyt010.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountCohort StudiesCoinfectionEuropeFemaleHIV InfectionsHumansLife ExpectancyNorth AmericaPregnancyPrognosisResidence CharacteristicsRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsViral LoadConceptsAntiretroviral Therapy Cohort CollaborationCombination antiretroviral therapyAntiretroviral therapyCohort CollaborationHIV biomarkersCohort studyClinical eventsHuman immunodeficiency virus-infected individualsEffective combination antiretroviral therapyIndividual cohort studiesVirus-infected individualsHIV Cohort StudyHIV-1 infectionImmune deficiency syndromeCause of deathART regimenHepatitis CAdult patientsAIDS eventsPatient demographicsRisk factorsDeficiency syndromeLiver enzymesPrognostic analysisDrug use
2012
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.
Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Annals Of Internal Medicine 2012, 157: 325-35. PMID: 22944874, PMCID: PMC3534765, DOI: 10.7326/0003-4819-157-5-201209040-00005.Peer-Reviewed Original ResearchConceptsCD4 cell countCD4 T-lymphocyte cell countMedian CD4 cell countT-lymphocyte cell countAntiretroviral therapy useHIV VLCell countNA-ACCORDHIV RNATherapy useViral loadU.S. National HIV/AIDS StrategyHealth outcomesNational HIV/AIDS StrategyCanadian HIV Trials NetworkHIV/AIDS StrategyActive antiretroviral therapyHIV outpatient clinicAnnual cross-sectional analysesHIV Cohort StudyProportion of participantsNational surveillance systemRelated health outcomesSimilar demographic characteristicsCross-sectional analysis
2009
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
Sterne J, May M, Costagliola D, de Wolf F, Phillips A, Harris R, Funk M, Geskus R, Gill J, Dabis F, Miró J, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole S. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 2009, 373: 1352-1363. PMID: 19361855, PMCID: PMC2670965, DOI: 10.1016/s0140-6736(09)60612-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Administration ScheduleEuropeFemaleHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPatient SelectionPractice Guidelines as TopicProportional Hazards ModelsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsHIV-1-infected patientsCombination antiretroviral therapyCD4 cell countAntiretroviral therapyCombination therapyCohort studyCell countCD4 cell count rangeCD4 cell count thresholdAntiretroviral-naive patientsProspective cohort studyHIV Cohort StudyRates of AIDSStart of treatmentHigh mortality rateAbsence of treatmentTiming of initiationDeath eventsCell count thresholdTherapy groupImmediate initiationPatientsMortality rateTherapyAIDS
2008
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Mugavero M, May M, Harris R, Saag M, Costagliola D, Egger M, Phillips A, Günthard H, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill M, Justice A, D'Arminio Monforte A, Lampe F, Miró J, Staszewski S, Sterne J. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS 2008, 22: 2481-2492. PMID: 19005271, PMCID: PMC2793403, DOI: 10.1097/qad.0b013e328318f130.Peer-Reviewed Original ResearchConceptsAntiretroviral-naïve patientsAntiretroviral therapyLopinavir/ritonavirVirologic failureClinical eventsThird drugART initiationCohort studyAntiretroviral Therapy Cohort CollaborationNaïve HIV-positive patientsHIV-positive patientsObservational cohort studyHIV Cohort StudyART regimenCohort CollaborationNaïve patientsClinical outcomesResidual confoundingClinical practicePatientsInhibitor backboneAbacavirNevirapineTherapyDrugs